Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases
Stem Cell Reviews and Reports · 2024
DOI: 10.1007/s12015-024-10715-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cell Reviews and Reports, 2024. Verfasst von Chengpeng Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, …. Hauptthemen laut MEDLINE: Genetic Therapy, Gene Editing, Hematopoietic Stem Cells, Hematologic Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, College Student Innovation and Entrepreneurship Training Program of Jiangsu Province, the National Key Research and Development Program of China.
Abstract (Originalsprache)
Base editors, developed from the CRISPR/Cas system, consist of components such as deaminase and Cas variants. Since their emergence in 2016, the precision, efficiency, and safety of base editors have been gradually optimized. The feasibility of using base editors in gene therapy has been demonstrated in several disease models. Compared with the CRISPR/Cas system, base editors have shown great potential in hematopoietic stem cells (HSCs) and HSC-based gene therapy, because they do not generate double-stranded breaks (DSBs) while achieving the precise realization of single-base substitutions. This precise editing mechanism allows for the permanent correction of genetic defects directly at their source within HSCs, thus promising a lasting therapeutic effect. Recent advances in base editors are expected to significantly increase the number of clinical trials for HSC-based gene therapies. In this review, we summarize the development and recent progress of DNA base editors, discuss their applications in HSC gene therapy, and highlight the prospects and challenges of future clinical stem cell therapies. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cyrus Tang Medical Institute, National Clinical Research Center for Hematologic Diseases, State Key Laboratory of Radiation Medicine and Protection, Collaborative Innovation Center of Hematology, Soochow Medical College…
ORCID-Profile: Peng Xu
Förderung
- the National Natural Science Foundation of China
- College Student Innovation and Entrepreneurship Training Program of Jiangsu Province
- the National Key Research and Development Program of China
Zitieren
APA
Zhang, C., Xu, J., Wu, Y., Xu, C., & Xu, P. (2024). Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases. Stem Cell Reviews and Reports. https://doi.org/10.1007/s12015-024-10715-5
Vancouver
Zhang C, Xu J, Wu Y, Xu C, Xu P. Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases. Stem Cell Reviews and Reports. 2024. doi:10.1007/s12015-024-10715-5
BibTeX
@article{Zhang2024,
author = {Zhang, Chengpeng and Xu, Jinchao and Wu, Yikang and Xu, Can and Xu, Peng},
title = {Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases},
journal = {Stem Cell Reviews and Reports},
year = {2024},
doi = {10.1007/s12015-024-10715-5}
}
EUVIMED